Dianthus Therapeutics, Inc. /DE/ (DNTH) Return on equity 2018–2025
Dianthus Therapeutics, Inc. /DE/ (DNTH) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-32.9%FY2025 · since FY2018: -39.5% → -32.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -32.9% | -8.8 pp |
| FY2024 | -24.1% | +1.7 pp |
| FY2023 | -25.8% | — |
| FY2019 | -54.4% | -14.9 pp |
| FY2018 | -39.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More DNTH financial trends
DNTH RevenueDNTH Net incomeDNTH Net marginDNTH Gross profitDNTH Gross marginDNTH Operating incomeDNTH Operating marginDNTH Operating cash flowDNTH Free cash flowDNTH Capital expendituresDNTH Stock buybacksDNTH Dividends paidDNTH Total assetsDNTH Total liabilitiesDNTH Shareholders’ equityDNTH overview →